Study of AFP464 +/- Faslodex in ER + Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm
Interventions: DRUG: AFP464|DRUG: AFP464 + Faslodex
Sponsor: Tigris Pharmaceuticals